Dipeptidyl peptidase‐4 inhibitors and pancreatitis risk: a meta‐analysis of randomized clinical trials
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Aim: Some observational studies reporting an increased risk of pancreatitis in association with Dipeptidyl Peptidase‐4 inhibitors ( DPP4i ) have raised concerns on the overall safety of this class. Aim of the present meta‐analysis is the systematic collection of information on pancreatitis in randomized clinical trials with DPP4i . Methods: Data Sources: an extensive Medline, Embase and Cochrane Database search for ‘vildagliptin’, ‘sitagliptin’, ‘saxagliptin’, ‘alogliptin’, ‘linagliptin’ and ‘dutogliptin’ was performed up to 1 March 2013. Study Selection: studies were included if they satisfied the following criteria: (i) randomized trials, (ii) duration ≥12 weeks, (iii) on type 2 diabetes and (iv) comparison of DPP4i with placebo or active drugs. The identification and the selection of studies, and the subsequent data extraction were performed independently by two authors. Mantel‐Haenszel odds ratio with 95% Confidence Interval ( MH‐OR ) was calculated for all the adverse events defined below. The principal outcome was the effect of DPP4i on the incidence of pancreatitis. Results: A total of 134 eligible trials were identified. The overall risk of pancreatitis and pancreatic cancer was not different between DPP4i and comparators ( MH‐OR : 0.93[0.51–1.69]; p = 0.82). Conclusions: It should be recognized that the number of observed cases of incident pancreatitis is small and the confidence intervals of risk estimates are wide. However, the present meta‐analysis do not suggest any increase in the risk of pancreatitis with DPP4i .
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies
Elashoff, M., Matveyenko, A. V., Gier, B., Elashoff, R., & Butler, P. C. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.02.018 · Cited by 944 · cited 2×
“An analysis based on the FDA’s database of reported adverse events suggested that sitagliptin could be associated with a 70% increase in the risk of pancreatitis, and a more than twofold increase in the risk of pancreatic cancer [4].”
BackgroundMethodCharbonnel, B., Karasik, A., Liu, J., Wu, M., Meininger, G., & for the Sitagliptin Study 020 Group (2006) · Diabetes Care · doi:10.2337/dc06-0706 · Cited by 790
Raz, I., Hanefeld, M., Xu, L., Caria, C., Williams-Herman, D., Khatami, H., & Sitagliptin Study 023 Group (2006) · Diabetologia · doi:10.1007/s00125-006-0416-z · Cited by 614 · cited 1×
“Sitagliptin NCT00411554 [16] NCT00411554 Voglibose 12 163 156 0 0 0 0 Aschner 2012 [43] NCT00751114 Glargine 24 264 237 0 0 0 0 NCT00700817 [1] NCT00700817 Detemir 78 219 446 0 1 0 1 NCT00449930 [16] NCT00449930 Metformin 24 528 522 0 0 0 0 Derosa 2010 [44] NR Metformin 52 75 76 NR NR NR NR Rosenstock 2012 [45] NCT006…”
Singh, S., Chang, H.-Y., Richards, T. M., Weiner, J. P., Clark, J. M., & Segal, J. B. (2013) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.2720 · Cited by 467
Incretin-Based Therapies for the Treatment of Type 2 Diabetes: Evaluation of the Risks and Benefits
Drucker, D. J., Sherman, S. I., Gorelick, F. S., Bergenstal, R. M., Sherwin, R. S., & Buse, J. B. (2010) · Diabetes Care · doi:10.2337/dc09-1499 · Cited by 316
Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes
Vilsbøll, T., Rosenstock, J., Yki‐Järvinen, H., Cefalu, W. T., Chen, Y., Luo, E., Musser, B., Andryuk, P. J., Ling, Y., Kaufman, K. D., et al. (2010) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01173.x · Cited by 305 · cited 1×
“Sitagliptin NCT00411554 [16] NCT00411554 Voglibose 12 163 156 0 0 0 0 Aschner 2012 [43] NCT00751114 Glargine 24 264 237 0 0 0 0 NCT00700817 [1] NCT00700817 Detemir 78 219 446 0 1 0 1 NCT00449930 [16] NCT00449930 Metformin 24 528 522 0 0 0 0 Derosa 2010 [44] NR Metformin 52 75 76 NR NR NR NR Rosenstock 2012 [45] NCT006…”
Rosenstock, J., Kim, S. W., Baron, M. A., Camisasca, R. ‐., Cressier, F., Couturier, A., & Dejager, S. (2007) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2006.00698.x · Cited by 255 · cited 1×
“Kikuchi 2010 [70] NCT00325117 Placebo 12 102 100 0 0 0 0 Fonseca 2007 [71] NCT00099931 Placebo 24 144 152 NR NR NR NR Goodman 2009 [72] NCT00351884 Placebo 24 248 122 NR NR NR NR Pi-Sunyer 2007 [73] NCT00120536 Placebo 24 262 92 NR NR NR NR NCT00494884 [16] NCT00494884 Placebo 24 268 134 0 0 0 0 Pan 2012 [74] NCT00822…”
Deacon, C. F., Mannucci, E., & Ahrén, B. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01603.x · Cited by 190
Self-citationBarnett, A. H., Charbonnel, B., Donovan, M., & Fleming, D. (2012) · Current Medical Research and Opinion · doi:10.1185/03007995.2012.665046 · Cited by 162 · cited 1×
“Alogliptin NCT01263483 [16] NCT01263483 Voglibose 12 155 75 0 0 0 0 NCT01263470 [16] NCT01263470 Placebo/Voglibose 12 322 158 0 0 0 0 NCT01318109 [16] NCT01318109 Placebo 12 188 100 0 0 0 0 NCT01318083 [16] NCT01318083 Placebo 12 209 103 0 0 0 0 NCT00755846 [16] NCT00755846 Placebo 12 222 43 0 0 0 0 NCT01318070 [16] N…”
Cited by
Garvey, W. T., Mechanick, J. I., Brett, E. M., Garber, A. J., Hurley, D. L., Jastreboff, A. M., Nadolsky, K., Pessah-Pollack, R., & Plodkowski, R. (2016) · Endocrine Practice · doi:10.4158/ep161365.gl · Cited by 1,914
Update on the treatment of type 2 diabetes mellitus
Marín-Peñalver, J. J., Martín-Timón, I., Sevillano-Collantes, C., & Cañizo-Gómez, F. J. D. (2016) · World Journal of Diabetes · doi:10.4239/wjd.v7.i17.354 · Cited by 647
Japanese Clinical Practice Guideline for Diabetes 2016
Haneda, M., Noda, M., Origasa, H., Noto, H., Yabe, D., Fujita, Y., Goto, A., Kondo, T., & Araki, E. (2018) · Diabetology International · doi:10.1007/s13340-018-0345-3 · Cited by 319
NRF2 activation by antioxidant antidiabetic agents accelerates tumor metastasis
Wang, H., Liu, X., Long, M., Huang, Y., Zhang, L., Zhang, R., Zheng, Y., Liao, X., Wang, Y., Liao, Q., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad6095 · Cited by 286
Li, L., Shen, J., Bala, M. M., Busse, J. W., Ebrahim, S., Vandvik, P. O., Rios, L. P., Malaga, G., Wong, E., Sohani, Z., et al. (2014) · BMJ · doi:10.1136/bmj.g2366 · Cited by 254
Metadata
- Authors
- Monami, M., Dicembrini, I., & Mannucci, E.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2013-07-28
- Volume
- 16
- Issue
- 1
- Pages
- 48-56
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W2087188973
- Cited by
- 101
- References
- 9
- FWCI
- 13.92
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Dipeptidyl peptidase‐4 inhibitors and pancreatitis risk: a meta‐analysis of randomized clinical trials. https://app.cochat.ai/papers/10.1111/dom.12176
- The paper
- Monami, M., Dicembrini, I., & Mannucci, E. (2014). Dipeptidyl peptidase‐4 inhibitors and pancreatitis risk: a meta‐analysis of randomized clinical trials. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.12176
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.